Gilead (GILD) CEO sells 10,000 shares under 10b5-1 plan filing

Gilead Sciences (GILD) insider filing: Chairman & CEO Daniel P. O’Day reported open‑market sales totaling 10,000 shares on 10/28/2025 under a Rule 10b5‑1 trading plan adopted on February 28, 2025.

Rhea-AI Filing Summary

Gilead Sciences (GILD) insider filing: Chairman & CEO Daniel P. O’Day reported open‑market sales totaling 10,000 shares on 10/28/2025 under a Rule 10b5‑1 trading plan adopted on February 28, 2025. The transactions were coded “S”.

He sold 7,978 shares at an average price of $119.5371 and 2,022 shares at $118.8223. Following the sales, he beneficially owns 581,203 shares directly, down from 583,225 before these trades. The filing notes price ranges for each trade, with full breakdowns available upon request to the company, the SEC, or shareowners.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 2 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 10,000 shs ($1.19M)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,978	$119.5371	$954K
Sale	Common Stock	2,022	$118.8223	$240K

Holdings After Transaction: Common Stock — 581,203 shares (Direct)

Footnotes (3)

1. F1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
2. F2. Sale prices for the transactions reported range from $119.08 to $120.06. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
3. F3. Sale prices for the transactions reported range from $118.61 to $119.06. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Gilead (GILD) disclose in this Form 4?

The Chairman & CEO, Daniel P. O’Day, reported selling a total of 10,000 shares on 10/28/2025 in open‑market transactions.

Were the GILD insider sales under a 10b5-1 plan?

Yes. The filing states the sales were made under a Rule 10b5‑1 trading plan adopted on February 28, 2025.

At what prices were the GILD shares sold?

Two trades: 7,978 shares at $119.5371 and 2,022 shares at $118.8223. The filing notes price ranges with details available upon request.

How many Gilead shares does Daniel O’Day hold after the sales?

The filing shows he now directly owns 581,203 shares.

What was Daniel O’Day’s ownership before these transactions?

The filing shows 583,225 shares directly owned prior to the reported sales.

What transaction code appears in the Form 4 for GILD?

Transaction code S, indicating an open‑market or private sale of non‑derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2025		S(1)		7,978	D	$119.5371(2)	583,225	D
Common Stock	10/28/2025		S(1)		2,022	D	$118.8223(3)	581,203	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

2. Sale prices for the transactions reported range from $119.08 to $120.06. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $118.61 to $119.06. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Daniel P. O'Day	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.